{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:02:53Z","timestamp":1780671773771,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clnu.2024.04.014","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:38:52Z","timestamp":1713195532000},"page":"1240-1249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Celiac disease: Hope for new treatments beyond a gluten-free diet"],"prefix":"10.1016","volume":"43","author":[{"given":"Maxim","family":"D'heedene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Vanuytsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-4996","authenticated-orcid":false,"given":"Lucas","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10344","key":"10.1016\/j.clnu.2024.04.014_bib1","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0140-6736(22)00794-2","article-title":"Coeliac disease","volume":"399","author":"Catassi","year":"2022","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2020.06.098","article-title":"Epidemiology, presentation, and diagnosis of celiac disease","volume":"160","author":"Lebwohl","year":"2021","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.clnu.2024.04.014_bib3","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1038\/ajg.2010.276","article-title":"Update on serologic testing in celiac disease","volume":"105","author":"Leffler","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clnu.2024.04.014_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","article-title":"Global prevalence of celiac disease: systematic review and meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14309\/ajg.0000000000002075","article-title":"American college of gastroenterology guidelines update: diagnosis and management of celiac disease","volume":"118","author":"Rubio-Tapia","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clnu.2024.04.014_bib6","first-page":"82","article-title":"Health benefits and adverse effects of a gluten-free diet in non-celiac disease patients","volume":"14","author":"Niland","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.clnu.2024.04.014_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/nu13113993","article-title":"The gluten-free diet for celiac disease and beyond","volume":"13","author":"Aljada","year":"2021","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.clnu.2024.04.014_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00394-016-1238-5","article-title":"Celiac disease: understanding the gluten-free diet","volume":"56","author":"Bascu\u00f1\u00e1n","year":"2017","journal-title":"Eur J Nutr"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clnu.2015.11.017","article-title":"Diet adherence and gluten exposure in coeliac disease and self-reported non-coeliac gluten sensitivity","volume":"36","author":"L\u00f8vik","year":"2017","journal-title":"Clin Nutr"},{"issue":"6","key":"10.1016\/j.clnu.2024.04.014_bib10","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1053\/j.gastro.2009.09.008","article-title":"Celiac disease: from pathogenesis to novel therapies","volume":"137","author":"Schuppan","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clnu.2024.04.014_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.clnu.2015.04.014","article-title":"Refractory celiac disease and EATL patients show severe malnutrition and malabsorption at diagnosis","volume":"35","author":"Wierdsma","year":"2016","journal-title":"Clin Nutr"},{"issue":"7","key":"10.1016\/j.clnu.2024.04.014_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072274","article-title":"Challenges of monitoring the gluten-free diet adherence in the management and follow-up of patients with celiac disease","volume":"13","author":"Wieser","year":"2021","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.clnu.2024.04.014_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.gastrohep.2017.12.002","article-title":"New coeliac disease treatments and their complications","volume":"41","author":"Vaquero","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clnu.2024.04.014_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.dld.2019.11.010","article-title":"Therapeutic options for coeliac disease: what else beyond gluten-free diet?","volume":"52","author":"Caio","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.clnu.2024.04.014_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072146","article-title":"New insights into non-dietary treatment in celiac disease: emerging therapeutic options","volume":"13","author":"Segura","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.04.014_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174434","article-title":"Current pharmacological approaches and potential future therapies for Celiac disease","volume":"909","author":"Kulkarni","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clnu.2024.04.014_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102268","article-title":"Celiac disease: new therapies on the horizon","volume":"66","author":"Dieckman","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"42","key":"10.1016\/j.clnu.2024.04.014_bib18","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.3748\/wjg.v18.i42.6036","article-title":"Celiac disease: prevalence, diagnosis, pathogenesis and treatment","volume":"18","author":"Gujral","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clnu.2024.04.014_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pathmechdis-031521-032634","article-title":"The immunobiology and pathogenesis of celiac disease","volume":"18","author":"Iversen","year":"2023","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"10.1016\/j.clnu.2024.04.014_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells11101667","article-title":"Features of ZED1227: the first-in-class tissue transglutaminase inhibitor undergoing clinical evaluation for the treatment of celiac disease","volume":"11","author":"B\u00fcchold","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1380-z","article-title":"Celiac disease: a comprehensive current review","volume":"17","author":"Caio","year":"2019","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.clnu.2024.04.014_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12072095","article-title":"Gluten degrading enzymes for treatment of celiac disease","volume":"12","author":"Wei","year":"2020","journal-title":"Nutrients"},{"issue":"35","key":"10.1016\/j.clnu.2024.04.014_bib23","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3748\/wjg.v19.i35.5837","article-title":"Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study","volume":"19","author":"Tack","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13587-7","article-title":"Randomized clinical trial: effective gluten degradation by Aspergillus Niger-derived enzyme in a complex meal setting","volume":"7","author":"K\u00f6nig","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.clnu.2024.04.014_bib25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3748\/wjg.v30.i11.1545","article-title":"Effect of Aspergillus Niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet","volume":"30","author":"Stefanolo","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten degradation, pharmacokinetics, safety, and tolerability of TAK-062, an engineered enzyme to treat celiac disease","volume":"161","author":"Pultz","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clnu.2024.04.014_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10620-011-1906-5","article-title":"Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials","volume":"57","author":"Siegel","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.clnu.2024.04.014_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2007.05.028","article-title":"Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue","volume":"133","author":"Gass","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clnu.2024.04.014_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clim.2009.11.001","article-title":"The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in\u00a0vivo","volume":"134","author":"Tye-Din","year":"2010","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.clnu.2024.04.014_bib31","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","article-title":"Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease","volume":"146","author":"L\u00e4hdeaho","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.clnu.2024.04.014_bib32","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1053\/j.gastro.2022.07.071","article-title":"Latiglutenase protects the mucosa and attenuates symptom severity in patients with celiac disease exposed to a gluten challenge","volume":"163","author":"Murray","year":"2022","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.clnu.2024.04.014_bib33","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1007\/s10620-017-4687-7","article-title":"Latiglutenase improves symptoms in seropositive celiac disease patients while on a gluten-free diet","volume":"62","author":"Syage","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.clnu.2024.04.014_bib34","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-016-4426-5","article-title":"AGY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease","volume":"62","author":"Sample","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.clnu.2024.04.014_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109972","article-title":"BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity","volume":"9","author":"McCarville","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2024.04.014_bib36","author":"Randomized"},{"issue":"5","key":"10.1016\/j.clnu.2024.04.014_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2007.03413.x","article-title":"The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study","volume":"26","author":"Paterson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clnu.2024.04.014_bib38","doi-asserted-by":"crossref","first-page":"G983","DOI":"10.1152\/ajpgi.00386.2020","article-title":"Larazotide acetate: a pharmacological peptide approach to tight junction regulation","volume":"320","author":"Slifer","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1756283X15616576","article-title":"The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate","volume":"9","author":"Khaleghi","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.clnu.2024.04.014_bib40","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.27321","article-title":"The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease","volume":"1","author":"Vanuytsel","year":"2013","journal-title":"Tissue Barriers"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2031695","article-title":"Lactobacillus rhamnosus CNCM I-3690 decreases subjective academic stress in healthy adults: a randomized placebo-controlled trial","volume":"14","author":"Wauters","year":"2022","journal-title":"Gut Microb"},{"issue":"10","key":"10.1016\/j.clnu.2024.04.014_bib42","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ajg.2012.211","article-title":"A\u00a0randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge","volume":"107","author":"Leffler","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clnu.2024.04.014_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.12147","article-title":"Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study","volume":"37","author":"Kelly","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.clnu.2024.04.014_bib44","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","article-title":"Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial","volume":"148","author":"Leffler","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.clnu.2024.04.014_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102845","article-title":"Hygiene hypothesis and autoimmune diseases: a narrative review of clinical evidences and mechanisms","volume":"20","author":"Murdaca","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.clnu.2024.04.014_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024092","article-title":"Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection","volume":"6","author":"McSorley","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clnu.2024.04.014_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017366","article-title":"Effect of hookworm infection on wheat challenge in celiac disease - a randomised double-blinded placebo controlled trial","volume":"6","author":"Daveson","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.clnu.2024.04.014_bib49","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000274","article-title":"Randomized, placebo controlled trial of experimental hookworm infection for improving gluten tolerance in celiac disease","volume":"11","author":"Croese","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.clnu.2024.04.014_bib50","article-title":"The contribution of the intestinal microbiota to the celiac disease pathogenesis along with the effectiveness of probiotic therapy","volume":"vol. 11","author":"Zolnikova","year":"2023"},{"key":"10.1016\/j.clnu.2024.04.014_bib51","article-title":"Gut microbiota alteration and its modulation with probiotics in celiac disease","volume":"vol. 11","author":"Saviano","year":"2023"},{"issue":"6","key":"10.1016\/j.clnu.2024.04.014_bib52","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s10238-022-00987-x","article-title":"The effects of probiotics on gastrointestinal symptoms and microbiota in patients with celiac disease: a systematic review and meta-analysis on clinical trials","volume":"23","author":"Mozafarybazargany","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.clnu.2024.04.014_bib53","first-page":"1584","article-title":"Probiotics for celiac disease: a systematic review and meta-analysis of randomized controlled trials","volume":"vol. 115","author":"Seiler","year":"2020"},{"issue":"JUN","key":"10.1016\/j.clnu.2024.04.014_bib54","article-title":"Vaccine immunotherapy for celiac disease","volume":"5","author":"Di Sabatino","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.clnu.2024.04.014_bib55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ebiom.2017.11.018","volume":"26","author":"Daveson","year":"2017","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.clnu.2024.04.014_bib56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2468-1253(17)30110-3","article-title":"Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies","volume":"2","author":"Goel","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.clnu.2024.04.014_bib57","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(22)00428-9","article-title":"Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study","volume":"8","author":"Tye-Din","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clnu.2024.04.014_bib58","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clnu.2024.04.014_bib60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S2468-1253(23)00107-3","article-title":"Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial","volume":"8","author":"Murray","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2032441","article-title":"A\u00a0randomized trial of a transglutaminase 2 inhibitor for celiac disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7796","key":"10.1016\/j.clnu.2024.04.014_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2003-8","article-title":"IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease","volume":"578","author":"Abadie","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.clnu.2024.04.014_bib64","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"L\u00e4hdeaho","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clnu.2024.04.014_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-020-0756-8","article-title":"Refractory celiac disease","volume":"22","author":"Hujoel","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"issue":"12","key":"10.1016\/j.clnu.2024.04.014_bib66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clnu.2024.04.014_bib67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41575-020-00378-1","article-title":"Current and emerging therapies for coeliac disease","volume":"18","author":"Kivel\u00e4","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clnu.2024.04.014_bib68","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2023.08.051","article-title":"Standardizing randomized controlled trials in celiac disease: an international multidisciplinary appropriateness study","volume":"166","author":"Lebwohl","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clnu.2024.04.014_bib69","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2014.07.022","article-title":"Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease","volume":"135","author":"Croese","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"16","key":"10.1016\/j.clnu.2024.04.014_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612800","article-title":"Old and new adjunctive therapies in celiac disease and refractory celiac disease: a review","volume":"24","author":"Valvano","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clnu.2024.04.014_bib80","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/apt.13266","article-title":"Randomised clinical study: Aspergillus Niger-derived enzyme digests gluten in the stomach of healthy volunteers","volume":"42","author":"Salden","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clnu.2024.04.014_bib81","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/apt.15435","article-title":"Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease","volume":"50","author":"Truitt","year":"2019","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:39:36Z","timestamp":1731746376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561424001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0261561424001201"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2024.04.014","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Celiac disease: Hope for new treatments beyond a gluten-free diet","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2024.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.","name":"copyright","label":"Copyright"}]}}